Drug Type Monoclonal antibody |
Synonyms- |
Target |
Mechanism CD160 inhibitors(CD160 molecule inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Alderaan Biotechnology SASStartup |
Active Organization Alderaan Biotechnology SASStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | FR | Alderaan Biotechnology SASStartup | 22 Aug 2024 |